Percutaneous vertebroplasty and kyphoplasty coverage for vertebral compression fractures

Coverage Summary

UnitedHealthcare Community Plan (Louisiana only) medical policy defining indications, required imaging exclusions, timing, and exclusions for percutaneous vertebroplasty and kyphoplasty. Policy status: RETIRED with retirement date April 1, 2026. Effective coverage period: May 1, 2025 – March 31, 2026. High-level coverage stance: mixed (procedure considered medically necessary in specific indications but evidence and recommendations vary).

Policy quick facts and thresholds

Policy numberCS330LA.D

StatusRETIRED

Effective dateMay 1, 2025

Retirement dateApril 1, 2026

Time from pain onset thresholdProcedure indicated within 4 months of pain onset

Vertebral height collapse exclusionSignificant vertebral collapse (e.g., vertebra reduced to less than one-third of its original height) — exclude

Scope summaryUnitedHealthcare Community Plan (Louisiana only) medical policy defining indications, required imaging exclusions, timing, and exclusions for percutaneous vertebroplasty and kyphoplasty

Medically Necessary and Related Criteria

Medically Necessary Coverage Criteria

Covered when ALL of the following are met:

ALL of the following

Pain causing Functional or Physical Impairment in a cervical, thoracic, or lumbar vertebral body<= 4 months from pain onset
Failure to respond to Optimal Medical Therapy
ONE of the following indications:
- Osteoporotic vertebral compression fracture (VCF)

Not Medically Necessary / Unproven Indications

Comparative Effectiveness & Evidence Summary

Percutaneous vertebroplasty (PVP) and kyphoplasty (KP/PKP) are minimally invasive procedures that inject bone cement (e.g., PMMA) into a vertebral body to relieve pain and stabilize fractures, primarily used for osteoporotic vertebral compression fractures and selected neoplastic lesions. The clinical evidence base is mixed: some open-label and nonblinded trials and meta-analyses report pain and functional improvements versus conservative care, whereas double-blind sham-controlled trials and Cochrane review conclusions raise uncertainty about routine benefit for vertebroplasty.

Evidence synthesis includes systematic reviews, meta-analyses, randomized controlled trials, cohort and retrospective studies, and health-technology assessments (HTAs). Major syntheses cited: Cochrane (Buchbinder et al. 2018) and Hayes HTA (2016, updated 2021) with nuanced conclusions; multiple network and pairwise meta-analyses (e.g., Xie 2017, Zhao 2017, Zuo 2018, Wang 2022) and RCTs/observational series that vary by indication, timing, and outcome measures.

Evidence citation	Key takeaway
Hayes 2017 (updated 2021)	Moderate-quality evidence KP may benefit some patients not responsive to conservative treatment; KP and VP provide similar improvements.
Buchbinder Cochrane 2018	High-to-moderate-quality evidence does not support vertebroplasty for routine practice versus sham; no demonstrable clinically important benefits and potential harms.
PVP vs conservative therapy (early pain relief)	PVP associated with higher early pain relief versus conservative treatment; no increase in adjacent fracture rate (Xie et al. 2017).
VP vs KP vs CT (network analysis)	VP best for pain relief; KP better for daily function, QoL and lower new fracture risk; overall comparable new fracture risk across treatments (Zhao et al. 2017).
PVP vs sham/open-label	Unblinded trials show benefit of PVP/BKP over conservative care; double-blind trials show PVP no more benefit than local anesthetic (Stevenson et al. 2014).
PKP vs PVP (single-level OVCF)	PKP superior for short-term VAS, kyphotic angle improvement, injected cement volume, and lower cement leakage; similar long-term VAS and adjacent fracture rates (Wang et al. 2015).
PVP/PKP in malignant VCFs	Clinically relevant improvements in pain, ODI, KPS; cement leakage common but rarely symptomatic; procedures safe and effective palliative options (Sorensen et al. 2019; Sadeghi-Naini et al. 2018).
PVP with BFMC (metastases with posterior wall defect)	Significant VAS and ODI reductions; asymptomatic cement leaks observed; 1-year local antitumor effect suggested (Zhan et al. 2024).
MWA + decompression + pedicle fixation vs fixation alone (spinal metastases)	MWA group had lower blood loss, lower early VAS, and longer progression-free survival (Zhang et al. 2024).
PVP/KP for vertebral hemangioma	Case series report substantial pain reduction and low complication rates; evidence limited by lack of comparative trials (Nambiar 2020; Narayana 2014; Hao & Hu 2012; Boschi 2012).
PVP/PKP for Kümmell disease	No statistical difference among PVP, PKP, and BFC in improving symptoms; PKP superior for kyphosis correction and BFC likely lowest cement leakage (Wang 2022 NMA; Zhang et al.).
Multiple myeloma	VP/KP associated with pain reduction, increased vertebral height, shorter hospital stay; low major complication rates (Reinas 2021; Nas 2016; Health Quality Ontario 2016).
AAOS 2010 (updated 2023)	Recommends against vertebroplasty for neurologically intact osteoporotic VCF; kyphoplasty considered an option with limited evidence.
ACR appropriateness criteria (2022)	Percutaneous vertebral augmentation usually appropriate for symptomatic osteoporotic VCF with bone marrow edema/intravertebral cleft and other specific variants.
ISASS (2019)	Endorses early treatment of painful VCFs with vertebral augmentation (preferentially kyphoplasty) based on level 1 evidence.
FDA / Device notes	Bone cement and bone tamps have FDA-cleared products; FDA approval informational only and not a sole basis for coverage.

Procedure and Regulatory Codes

Applicable CPT procedure codes (reference only)CPT

22510	Percutaneous vertebroplasty, 1 vertebral body, cervicothoracic (bone biopsy included when performed), unilateral or bilateral injection, inclusive of imaging guidance
22511	Percutaneous vertebroplasty, 1 vertebral body, lumbosacral (bone biopsy included when performed), unilateral or bilateral injection, inclusive of imaging guidance
22512	Percutaneous vertebroplasty, each additional vertebral body (List separately in addition to code for primary procedure)
22513	Percutaneous vertebral augmentation (kyphoplasty), 1 vertebral body, thoracic, inclusive of imaging guidance
22514	Percutaneous vertebral augmentation (kyphoplasty), 1 vertebral body, lumbar, inclusive of imaging guidance
22515	Percutaneous vertebral augmentation (kyphoplasty), each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)

Regulatory / device information (informational)mixed

NDN/LOD	FDA product codes referenced for PMMA bone cement (informational only)
HRX/HXG	FDA product codes referenced for bone tamps (informational only)

Provider Actions & Documentation Requirements

Prior Authorization

Prior authorization implied by medical policy

Obtain prior authorization per the member’s plan procedures before scheduling vertebroplasty or kyphoplasty.

Policy number: CS330LA.D (Retired April 1, 2026)

Documentation Required

Imaging documentation required

CT or MRI must document exclusion of other spinal pain generators and confirm there is no spinal cord compression, no significant vertebral collapse (e.g., vertebra reduced to less than one‑third of its original height), and no healed vertebral compression fracture.

Definitions

Functional or Physical Impairment: Deviation from normal function causing a significantly limited capacity to move, coordinate actions, or perform physical activities.

Optimal Medical Therapy: First-line noninvasive treatments (analgesics, bed rest, bracing) employed before invasive procedures.

Osteonecrosis: Bone disease from reduced blood flow (e.g., Kümmell disease) that increases fracture risk; nonsurgical treatments may relieve symptoms but do not cure.

Vertebral Hemangiomas: Benign vascular spine tumors; aggressive subtype may cause extra‑osseous extension, bone expansion, and compression fractures.

PVP: Percutaneous vertebroplasty.

PKP / KP / BKP: Percutaneous kyphoplasty (balloon kyphoplasty).

BFC / BFMC: Bone‑filling container / bone‑filling mesh containers.

OVCF: Osteoporotic vertebral compression fracture.

Failure of conservative therapy: Pain refractory to oral medications (NSAIDs and/or narcotics), contraindication to such medications, or requirement for parenteral narcotics and hospital admission (ACR definition).

Kümmell's disease (KD): Osteonecrosis‑related delayed vertebral collapse / nonhealing vertebral fracture, sometimes with intravertebral cleft.

Comparative Procedure Findings (select evidence points)

Comparative evidence in Kümmell's disease across PVP, PKP, and bone‑filling mesh containers (BFC) shows: no consistent statistical difference among PVP, PKP, and BFC in improving clinical symptoms (pain and disability) in combined analyses.

PKP (kyphoplasty) is consistently more effective for radiographic correction of kyphosis and certain vertebral height measures compared with PVP.

BFC (bone‑filling mesh containers) are associated with the lowest rates of cement leakage in comparative analyses.

PKP is associated with greater resource consumption (larger cement volume, longer operative and fluoroscopy times, more blood loss, and higher cost) compared with PVP.

Revision History

2025-05-01supporting_information_update

Supporting Information: Clinical Evidence and FDA sections updated to reflect the most current information (updated 05/01/2025); previous policy version CS330LA.C archived.

2026-04-01retirementLatest

Policy marked Retired effective April 1, 2026; Louisiana plan membership disenrolled on Apr. 1, 2026 (material).